Evidence map›Paper›PMID 35315001›Full record

ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2022

An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?

R G Vitale, J Afeltra, S Seyedmousavi, S L Giudicessi, S M Romero

Open access · bronzeAbstract readReview
In one paragraph

Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

R G VitaleConsejo Nacional de Investigaciones Científicas Y Tecnológicas (CONICET), Buenos Aires, Argentina. rvitale@conicet.gov.ar.
J AfeltraUnidad de Parasitología. Sector Micología. Hospital J.M. Ramos Mejía, Buenos Aires, Argentina.
S SeyedmousaviMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
S L GiudicessiFacultad de Farmacia Y Bioquímica, Cátedra de Biotecnología, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina.
S M RomeroConsejo Nacional de Investigaciones Científicas Y Tecnológicas (CONICET), Buenos Aires, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARHospital Ramos Mejía · ARNational Institutes of Health Clinical Center · USUniversity of Buenos Aires · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2019, severe acute respiratory syndrome caused by CoV-2 virus became a pandemic worldwide, being the fast spread of the disease due to the movement of infected people from one country to another, from one continent to another, or within the same country. Associated comorbidities are important factors that predispose to any fungal coinfections. Because of the importance of fungal infections in COVID-19 patients, the aim of this work was to collect data of the more encountered mycoses related to patients undergoing this disease. Aspergillosis was the first COVID-19-related fungal infection reported, being A. fumigatus the most frequent species for CAPA. Other fungal infections related include mainly candidiasis and mucormycosis, being Rhizopus spp. the more prevalent species found. Influenza-associated pulmonary aspergillosis is well documented; thus, similar complications are expected in severe forms of COVID-19 pneumonia. Therefore, in patients with COVID-19, it is important to take special attention to the surveillance and suspicion of fungal coinfections that might worsen the patient's prognosis.

Indexed as

CoinfectionCOVID-19MycosesHumansPandemicsSARS-CoV-2AspergillusAssociated pulmonary aspergillosis (CAPA)CandidaMucormycosisNon-Candida yeastsPneumonia

Identifiers

PMID35315001
PMCPMC8936386
OpenAlexW4220717257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.